The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer

Aging Male

Volumn 8, Issue 3-4, 2005, Pages 207-212

  Boxer, R S ^a   Kenny, A M ^a   Dowsett, R ^a   Taxel, P ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Androgen deprivation; Body composition; Prostate cancer; Sarcopenia

Indexed keywords

FAT; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PLACEBO;

ADULT; ANDROGEN THERAPY; ARTICLE; BODY COMPOSITION; BODY FAT; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME IMMUNOASSAY; HUMAN; LIFESTYLE; MALE; MEDICAL RESEARCH; MUSCLE; MUSCLE ATROPHY; MUSCLE MASS; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SKELETAL MUSCLE; TESTOSTERONE BLOOD LEVEL;

ADIPOSITY; AGED; ANDROGEN ANTAGONISTS; BODY COMPOSITION; CASE-CONTROL STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 30344485119     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530500361226     Document Type: Article

References (41)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK, editors. SEER Cancer Statistics Review, 1973-1997, National Cancer Institute, Bethesda, MD:NIH Pub No. 00-2789, 2000.
2. Garnick M. The Leuprolide Study Group. Leuprolide versus diethylstilbesterol for metastatic PCa. New Eng J Med 1984;311:1281-1286.
3. Sharifi RS, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide Acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced PCa. Clin Therapeutics 1996;18:647-657.
4. Huggins C, Hodges C. Studies in PCa. I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1941;1:293-297.
5. Rosenberg IH. Summary comments. Am J Clin Nutr 1989;50:1231-1233.
6. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol Med Sci 2000;55A:M716-M724.
7. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among elderly in New Mexico. Am J Epidemiol 1998;147:755-763.
8. Iannuzzi Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol Med Sci 2002;57(12):M772-M777.
9. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Age Dev 1999;107:123-136.
10. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50(5):889-896.
11. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85-M94.
12. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-M156.
13. Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 2000;55(12):M706-M708.
14. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002;95(10):2136-2144.
15. Basaria S, Lieb J II, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56(6):779-786.
16. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004;63:742-745.
17. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 1990;39:1314-1319.
18. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167(6):2361-2367.
19. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56(5):M266-M272.
20. Wang ZM, Visser M, Ma R, Baumgartner RN, Kotler D, Gallagher D, Heymsfield SB. Skeletal muscle mass: evaluation of neutron activation and dual-energy x-ray absorptiometry methods. J Appl Physiol 1996;80(3):824-831.
21. Visser M, Pahor M, Tylavsky F, Kritchevsky SB, Cauley JA, Newman AB, Blunt BA, Harris TB. One- and two-year change in body composition as measured by DXA in a population-based cohort of older men and women. J Appl Physiol 2003;94(6):2368-2374.
22. Baumgartner RN. Body composition in healthy aging. Ann NY Acad Sci 2000;904:437-448.
23. Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB. Health ABC study investigators. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003;51(11):1602-1609.
24. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87(2):599-603.
25. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004;22(13):2546-2553.
26. Kenny AM, Dawson L, Kleppinger A, Iannuzzi-Sucich M, Judge JO. Prevalence of sarcopenia and predictors of skeletal muscle mass in non-obese women who are long-term users of estrogen-replacement therapy. J Gerontol A Biol Sci Med Sci 2003;58(5):M436-M440.
27. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endo Metab 1997;82:407-413.
28. Bashin S, Woodhouse L, Casburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrin Metab 2001;281:E1172-E1181.
29. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen deprivation therapy. J Urology 2000;163:1743-1746.
30. Stone P, Hardy J, Huddart R, A'Hern A, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000;36:1134-1141.
31. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003;21(9):1653-1659.
32. Kyle UG, Genton, L, Hans, D, Karesgard, L, Slosman, DO, Pichard, C. Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 19 and 94 years. Eur J Clin Nutr 2001;55:663-672.
33. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, Nyren O. Body size and PCa: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-389.
34. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, Lynch CF. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 2000;10:361-369.
35. Cerhan JR, Torner JC, Lynch CF, Rubenstein LM, Lemke JH, Cohen MB, Lubaroff DM, Wallace RB. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997;8:229-238.
36. Talamini R, La Vecchia C, Decarli A, Negri E, Franceschi S. Nutrition, social factors and prostatic cancer in a Northern Italian population. Br J Cancer 1986;53: 817-821.
37. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:1417-1421.
38. Pietrobelli A, Heymsfield SB, Wang ZM, Gallagher D. Multi-component body composition models: recent advances and future directions. Eur J Clin Nutr 2001;55(2):69-75.
39. Maturo G, Vespasiani G, Mohamed EI. Evaluating body composition of Italian prostate cancer patients without metastases. Acta Diabetol 2003;40(Suppl. 1):S168-S170.
40. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001;86(6):2787-2791.
41. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood, KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol Med Sci 2002;57(5):M321-M325.